Effects of CB-154 (2-Br-alpha-ergocryptine) on prolactin and growth hormone release in an acromegalic patient with galactorrhea.
An acromegalic patient with galactorrhea was treated with an ergot alkaloid, 2-Br-alpha-ergocryptine (CB-154). Serum prolactin decreased rapidly to normal level by CB-154 and the complete cessation of galactorrhea was noted. The inhibitory effect of CB-154 On growth hormone (GH) release was also noted, but slight. The mechanism of inhibitory action of CB-154 on both prolactin and GH secretion was discussed in connection with the experimental model of pituitary tumors, in which both hormones were produced by a single type of tumor cells. The discontinuation of CB-154 treatment was associated with the return of both prolactin and GH levels to the initial high values with resumption of galactorrhea.
D000172:Acromegaly / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005687:Galactorrhea / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D007980:Levodopa / Q000627:therapeutic use; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*
D004873:Ergolines; D007980:Levodopa; D011388:Prolactin; D013006:Growth Hormone